Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.81 |
| ▸ | SIGMAR1 | Q99720 | 8/20 | 0.53 |
| ▸ | MPO | P05164 | 1/20 | 0.48 |
| ▸ | GRM5 | P41594 | 1/20 | 0.47 |
| ▸ | BCHE | P06276 | 3/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
| ▸ | MAOA | P21397 | 1/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9777453 | 0.84 | SMN1; SMN2 (0.64) | SMN1; SMN2MEN1KMT2AKDM1AMAOA | |
| SCHEMBL25376464 | 0.82 | SMN1; SMN2 (0.71) | SMN1; SMN2MEN1KMT2AKDM1AMAOA | |
| SCHEMBL10144374 | 0.80 | SMN1; SMN2 (0.59) | SMN1; SMN2GRM5KMT2A | |
| SCHEMBL9777407 | 0.80 | SMN1; SMN2 (0.68) | SMN1; SMN2MEN1KMT2AKDM1AMAOA | |
| SCHEMBL10483884 | 0.80 | SMN1; SMN2 (0.59) | SMN1; SMN2MEN1KMT2AKDM1AMAOA | |
| SCHEMBL21986550 | 0.80 | SMN1; SMN2 (0.59) | SMN1; SMN2SIGMAR1MEN1KMT2AKDM1A | |
| SCHEMBL10483914 | 0.79 | SMN1; SMN2 (0.62) | SMN1; SMN2MEN1KMT2AKDM1AMAOA | |
| SCHEMBL9967158 | 0.78 | SMN1; SMN2 (0.57) | SMN1; SMN2SIGMAR1MEN1KMT2AKDM1A | |
| SCHEMBL943003 | 0.78 | SMN1; SMN2 (0.64) | SMN1; SMN2MEN1KMT2AKDM1AMAOA | |
| SCHEMBL22564633 | 0.77 | SMN1; SMN2 (0.64) | SMN1; SMN2GRM5MEN1KMT2AKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120004262-A1 | PHENYLCYCLOPROPYLAMINE DERIVATIVES AND THEIR MEDICAL USE | ORYZON GENOMICS, S.A. (ES) | 2012-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120004262-A1 | PHENYLCYCLOPROPYLAMINE DERIVATIVES AND THEIR MEDICAL USE | PNMT, ABCB1, SNCA | SMN1; SMN2 158/4885SIGMAR1 911/4885MPO 3521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.